乳腺浸润性导管癌性激素受体与耐药因子的相关性研究

目的探讨非特殊性乳腺浸润性导管癌雌、孕激素受体（ER、PR）、癌基因（CerbB-2）表达与常用化疗药物耐药因子的相关性及其临床意义。方法应用免疫组织化学方法观察65例乳腺浸润性导管癌性激素受体ER、PR、CerbB-2及耐药因子P-糖蛋白（P—gp）、谷胱甘肽-S-转移酶-π（GST-Ⅱ）、DNA拓扑异构酶Ⅱ（TOPOⅡ）表达，并进一步对不同治疗前提分组中各耐药因子表达进行比较分析。结果患者大都存在多药耐药现象（81．6％），耐药情况与肿瘤分化程度无关，与是否绝经无关，但与癌肿的临床分期有关；不同治疗前提分组中ER（-），CerbB-2低表达纽TOPOⅡ的表达与其它组比较差异有统计学意义（P〈0．05）。结论联合检测乳腺浸润性导管癌组织中ER、CerbB-2和耐药因子TOPOⅡ的表达，对乳腺浸润性导管癌治疗方案的制定和预后判断有重要的参考价值。

The correlation of sex hormone receptor and drug resistance factor in infiltrating ductal carcinoma of breast

Objective To investigate correlation and clinical significantce of theexpression of ER, PR, CerbB-2 and multiple drug resistance gene in infiltratingductal carcinoma of breast. Methods Sixtyfive cases with infiltrating ductal carcinoma of breast were detected by immunohistochemical method for ER, PR, CerbB-2, P-gp, GST-π, and TOPO Ⅱ , and expression of multiple drug resistance gene were analyzed in various groups. Results The positive expression rate of drug resistance was 81. 6 %, which was related to clinical stage but no related to differentiation and menopause. Expression of TOPO Ⅱ has significant difference in the negative expressions of ER and CerbB-2 to compare other groups. Conclusion The expression of ER, CerbB-2 and TOPOⅡ in breast carcinoma tissues has an instructive significance for leading clinical therapy and predicting prognostic of patients with infiltra- ting ductal carcinoma of breast.